Valuation: Sarepta Therapeutics, Inc.

Market Cap 1.85B 1.64B 1.53B 1.4B 2.64B 178B 2.66B 18.55B 7.19B 90.84B 6.94B 6.79B 292B P/E 2026 *
5.58x
P/E 2027 * 40.1x
Enterprise Value 1.59B 1.41B 1.32B 1.2B 2.26B 153B 2.28B 15.93B 6.17B 77.98B 5.96B 5.83B 250B EV / Sales 2026 *
0.86x
EV / Sales 2027 * 0.88x
Free-Float
94.53%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week-6.27%
Current month-3.95%
1 month-22.22%
3 months-9.23%
6 months-24.67%
Current year-18.68%
1 week 17.21
Extreme 17.21
18.74
1 month 17.21
Extreme 17.21
23.22
Current year 14.68
Extreme 14.68
24.68
1 year 14.68
Extreme 14.68
25.32
3 years 10.42
Extreme 10.415
173.25
5 years 10.42
Extreme 10.415
173.25
10 years 10.42
Extreme 10.415
181.83
Manager TitleAgeSince
Chief Executive Officer 60 2026-07-27
Director of Finance/CFO 47 2025-07-15
Director of Finance/CFO 50 2020-12-13
Director TitleAgeSince
Chairman 73 2015-04-15
Director/Board Member 87 2010-05-31
Director/Board Member 67 2015-06-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Tax

Chief Financial Officer

-13,272 0.0126%
9/4/26 Tax

General Counsel

-22,025 0.0209%
9/4/26 Tax

Chairperson

-24,799 0.0235%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-6.27%-22.70%-85.15% 1.85B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
-0.95%-4.05%+20.54%+41.71% 333B
-1.46%-2.89%+10.57%+32.81% 267B
-1.35%-5.43%-6.17%+8.98% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.72%-3.82%+21.19%+44.27% 369.9B
Weighted average by Cap. -0.60%-3.54%+29.05%+70.49%

Financials

2026 *2027 *
Net sales 1.84B 1.63B 1.52B 1.39B 2.62B 177B 2.64B 18.43B 7.14B 90.25B 6.9B 6.75B 290B 1.38B 1.23B 1.14B 1.04B 1.97B 133B 1.99B 13.86B 5.37B 67.85B 5.18B 5.07B 218B
Net income 366M 325M 303M 276M 521M 35.15B 526M 3.67B 1.42B 17.97B 1.37B 1.34B 57.67B 39.41M 35.02M 32.69M 29.79M 56.19M 3.79B 56.71M 396M 153M 1.94B 148M 145M 6.22B
Net Debt -262M -232M -217M -198M -373M -25.15B -376M -2.63B -1.02B -12.86B -982M -961M -41.26B -635M -564M -526M -480M -905M -61.03B -913M -6.37B -2.47B -31.2B -2.38B -2.33B -100B
Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Employees
835
Date Price Change Volume
26-10-02 US$17.50 -0.40% 2,549,723
26-10-01 US$17.57 -3.57% 2,885,278
26-09-30 US$18.22 -2.25% 1,995,000
26-09-29 US$18.64 -0.85% 1,368,566
26-09-28 US$18.80 +0.70% 2,268,390
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
17.50USD
Average target price
21.73USD
Spread / Average Target
+24.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRPT Stock